Rznomics, Roche partner to evaluate RZ-001 in combination with atezolizumab in HCC patients
Under the partnership, Roche will provide atezolizumab for use in combination with RZ-001, an enzyme-based cancer gene therapy,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Nov 23
Under the partnership, Roche will provide atezolizumab for use in combination with RZ-001, an enzyme-based cancer gene therapy,…
13 Nov 23
ProstACT GLOBAL is the first late-stage study to assess TLX591 in adult patients with PSMA-positive metastatic castrate-resistant prostate…
13 Nov 23
Trial expected to reach the primary endpoint of progression free survival in the second half of 2025
10 Nov 23
In these studies, remibrutinib achieved all primary and secondary endpoints at Week 12 and the results showed that…
09 Nov 23
In the CorEvitas registry, a significant portion of people with treatment-resistant active PsA and using the Janssen Pharmaceuticals…
07 Nov 23
The Phase 2 trial assessed BI 690517 on top of empagliflozin against placebo for 14 weeks and the…
06 Nov 23
The results showed statistically significant and clinically meaningful reductions in UACR, used to assess albuminuria, at 12 weeks…
06 Nov 23
The results were consistent across every month and every-other-month dosing of Izervay against sham through two years of…
03 Nov 23
The reduction in systolic blood pressure during treatment in the Phase 4 trial was more significant at Week…
02 Nov 23
The anti-PD-1 therapy delivered a statistically significant improvement in OS as an adjuvant treatment in RCC patients at…